PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 863369

[Tonsillectomy in patients with bleeding disorders].

H Gastpar
View original source ↗Export metadata ↓

Abstract

When injury of a major vessel can be ruled out as the cause of bleeding after tonsillectomy, a discrete disturbance of hemostasis must be considered. These are mainly slight thrombopathies or a pathologically increased fibrinolysis, which were not detected by routine tests and the past history. In former times severe bleeding disorders were a strict contra-indication for tonsillectomy. Under the supposition of an exact coagulogram and the substitution of highly purified factor concentrates the risk of severe post-tonsillectomy hemorrhages in such patients today is nearly the same as in patients with a normal hemostase.

Explore related subjects

Antifibrinolytic AgentsBlood Coagulation FactorsBlood Platelet DisordersFibrinHemorrhageHemorrhagic DisordersHumansPostoperative ComplicationsTissue AdhesivesTonsillectomyEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Gastpar. 1977-05-19. [Tonsillectomy in patients with bleeding disorders].. https://pubmed.ncbi.nlm.nih.gov/863369/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia.

OBJECTIVE: Recombinant factor VIIa (rFVIIa, NovoSeven) has proven efficacy in treating bleeding in hemophilia patients with inhibitors. A rFVIIa analog with mutations V158D/E296V/M298Q (NN1731) exhibits increased procoagulant activity in in vitro and in vivo models. The aim of this work was to define the effects of NN1731 toward factor X activation, platelet activation, thrombin generation, and fibrin clot formation and stability. METHODS AND RESULTS: In a cell-based in vitro model of hemophilia, rFVIIa and NN1731 similarly increased factor X activation on tissue factor-bearing cells; however, NN1731 exhibited 30-fold higher factor Xa generation on platelets than similar rFVIIa concentrations. NN1731-mediated thrombin generation depended on platelet activation, but NN1731 did not directly activate platelets. NN1731 produced 4- to 10-fold higher maximal thrombin generation rates than equal rFVIIa concentrations. Both rFVIIa and NN1731 shortened clotting times in the absence of factors IX and VIII; however, NN1731 did so at 50-fold lower concentrations than were required of rFVIIa. In fibrinolytic conditions, both rFVIIa and NN1731 increased fibrin formation and stability; however, NN1731 was effective at 50-fold lower concentrations than were required of rFVIIa. CONCLUSIONS: By increasing factor Xa generation, NN1731 promotes the formation of thrombin and a stable clot to a greater degree than rFVIIa.

Antifibrinolytic Agents↗
PubMed2006

BcSAK1, a stress-activated mitogen-activated protein kinase, is involved in vegetative differentiation and pathogenicity in Botrytis cinerea.

The gene bcsak1, encoding a mitogen-activated protein kinase (MAPK) of Botrytis cinerea, was cloned and characterized. The protein has high homology to the yeast Hog1 and to corresponding MAPKs from filamentous fungi, but it shows unique functional features. The protein is phosphorylated under osmotic stress, specific fungicides, and oxidative stress mediated by H(2)O(2) and menadione. Northern blot analyses indicate that only a subset of typical oxidative stress response genes is regulated by BcSAK1. In contrast to most other fungal systems, Deltabcsak1 mutants are significantly impaired in vegetative and pathogenic development: they are blocked in conidia formation, show increased sclerotial development, and are unable to penetrate unwounded plant tissue. These data indicate that in B. cinerea the stress-activated MAPK cascade is involved in essential differentiation programs.

Antifibrinolytic Agents↗